In France, many people consult “bonesetters” for several medical reasons. Little is known about them. We aimed to investigate the practices of traditional healers in France as well as their profile and that of their customers.This was a survey carried out in Metropolitan France. A 33-item questionnaire developed by a multidisciplinary group was sent to a sample of 148 traditional healers found on the Internet and by word of mouth.Of the 148 questionnaires sent, 89 (60.1 %) were returned and 67 (45.3 %) were analyzed: 51.5 % (n = 34) of respondents were men, and the mean (±standard deviation) age was 51.6 ± 11.6 years. The respondents considered that they had received a gift of healing and were mainly magnetic healers (68.2 %). They became aware of this gift at a mean age of 19.9 ± 14.1 years. The traditional healers practiced mainly in rural areas (54.5 %), at home (59.1 %), and used their hands to transmit energy (95.5 %). They advertised their practice mainly by word of mouth (89.4 %) and had a predominantly female clientele (78.1 %). Various diseases were treated, with the most frequent being subjective complaints (pain, stress, fatigue, insomnia) and dermatological complaints (eczema, accidental and post–herpes-zoster burns, psoriasis, and warts). Most respondents considered their activities to be complementary to conventional medicine, and 10.9 % considered them more effective. Some indicated that they did not consider themselves “healers” but rather “providers of relief”.The results of this survey provide a better understanding of this network of local care that revolves around medicine.

Les dermatoses inflammatoires chroniques (DIC) peuvent grever de manière significative la qualité de vie des patients. Leurs traitements ont fait l’objet d’avancées majeures ces dernières années. Très peu de données à long terme sur la vision des patients vis-à-vis de leur DIC et de leurs traitements ont été rapportées. Un registre français, prospectif et multicentrique a été mis en place pour quantifier l’impact et l’évolution de la qualité de vie des patients suivis pour une des 4 DIC de stade modéré à sévère, les plus fréquentes et ayant le plus d’impact sur le quotidien, le psoriasis (PS), la maladie de Verneuil (MV), la dermatite atopique (DA) et l’urticaire chronique (UC), durant une période de suivi de quatre ans. Les patients adultes vus en pratique courante étaient inclus à l’initiation ou lors de la modification d’un traitement systémique ou biologique. Lors de la visite d’inclusion, puis tous les 6 mois pendant 4 ans, les résultats rapportés par les patients (PRO) et les données cliniques de ces maladies et de leurs traitements ont été recueillies. Au total, 2058 patients ont été inclus dans 24 centres : 1137 PS, 413 DA, 301 MV et 207 UC. Ces maladies avaient un impact majeur pour plus de 90 % des patients affectant la vie quotidienne, familiale et professionnelle. Selon le SF-12, l’impact des quatre maladies était à la limite du pathologique pour la santé physique et sévère pour la santé mentale. Au cours des 6 mois précédant l’inclusion, 17,7 % (PS), 27,9 % (DA), 43,1 % (MV) et 43,6 % (UC) des patients se sont absentés du travail en raison de leur maladie. 26,3 % des patients atteints de MV ont été hospitalisés (vs 8,1 %, 5,8 % et 13 % des patients atteints de PS, DA ou UC, respectivement). Près de la moitié des patients MV (majoritairement des femmes d’un âge médian de 32 ans) étaient toujours célibataires. Plus de 25,8 % des patients atteints de MV étaient au chômage et ceux qui avaient un emploi occupaient principalement des postes peu qualifiés. Malgré le poids important de ces 4 DIC, seuls 6,2 % des patients recevaient un traitement systémique conventionnel et 14,2 % un traitement biologique avant la visite d’inclusion. Après cette première visite, 87,4 % de ces patients recevaient un traitement systémique ou biologique. Les DIC affectent environ un adulte français sur dix. Les études qui quantifient le fardeau des DIC sont principalement des évaluations ponctuelles qui n’évaluent pas l’impact dynamique des DIC qui peut s’accumuler avec le temps ou changer en termes de dimensions affectées (physique, psychologique, socioprofessionnelles, sentiments des patients à l’égard de leur maladie, de leurs traitements…). Malgré la révolution thérapeutique dans ces domaines, nous constatons encore dans la pratique quotidienne l’impact majeur de ces DIC sur la qualité de vie de ces patients et de leur famille. Le poids de ces DIC au niveau individuel et sociétal tend à être sous-estimé, y compris parfois par les dermatologues. Ces DIC (en particulier la MV) ont un impact majeur sur tous les aspects de la qualité de vie des patients. La faible utilisation de base des traitements systémiques au regard du fardeau élevé de ces DIC suggèrent un usage sous optimale des traitements pour ces patients. L’évaluation dynamique et à long terme des changements apportés par l’initiation ou l’optimisation de ces traitements sur l’évolution de la vie des patients sera étudiée prospectivement au cours des 4 ans de suivi de ce registre.

Journal of the European Academy of Dermatology and VenereologyAccepted Articles LETTER TO THE EDITOR Janus kinase inhibitors (JAKi) for the treatment of atopic dermatitis: real-life data on efficacy and safety in light of the Pharmacovigilance Risk Assessment Committee (PRAC) recommended measures Z. Reguiai, Corresponding Author Z. Reguiai [email protected] Department of Dermatology, Polyclinique Courlancy, Reims-Bezannes, France Correspondence Ziad REGUIAI, Postal address: Department of Dermatology, Polyclinique Courlancy-Bezannes, 89 rue Louis-Victor de Broglie, 51430 Bezannes. Email: [email protected], Tel: 0033352150808, Fax: 0033352150809Search for more papers by this authorP. A. Becherel, P. A. Becherel Dermatology and Clinical Immunology Unit, Antony Hospital, Antony, FranceSearch for more papers by this authorA. C. Fougerousse, A. C. Fougerousse orcid.org/0000-0002-2850-867X Hôpital d'Instruction des Armées Begin, Saint Mandé, FranceSearch for more papers by this authorG. Chaby, G. Chaby CHU Amiens- Picardie, Amiens, FranceSearch for more papers by this authorJ. L. Perrot, J. L. Perrot CHU Saint Etienne, Saint-Priest-en-Jarez, FranceSearch for more papers by this authorE. Begon, E. Begon Centre hospitalier René Dubos, Pontoise, FranceSearch for more papers by this authorC. Jacobzone-Lévêque, C. Jacobzone-Lévêque Centre hospitalier Bretagne Sud, Lorient, FranceSearch for more papers by this authorC. Boulard, C. Boulard GH, Le Havre, Montivilliers, FranceSearch for more papers by this authorA. Badaoui, A. Badaoui Cabinet Médical, Paris, FranceSearch for more papers by this authorC. Poreaux, C. Poreaux Centre de dermatologie Stanislas, , Nancy, Clinique Paster, Essey les Nancy, FranceSearch for more papers by this authorL. David, L. David Hopital Saint Joseph, Marseille, FranceSearch for more papers by this authorN. Quiles-Tsimaratos, N. Quiles-Tsimaratos Hopital Saint Joseph, Marseille, FranceSearch for more papers by this authorD. Lons-Danic, D. Lons-Danic Hôpital Paris Saint Joseph, Paris, FranceSearch for more papers by this authorC. Fite, C. Fite Hôpital Paris Saint Joseph, Paris, FranceSearch for more papers by this authorA.-L. Liegeon, A.-L. Liegeon Centre hospitalier régional Metz-Thionville, Thionville, FranceSearch for more papers by this authorA. Patchinsky, A. Patchinsky Centre hospitalier régional Metz-Thionville, Thionville, FranceSearch for more papers by this authorJ. Parier, J. Parier Centre de Santé Sabouraud, hôpital Saint-Louis, Paris, France Cabinet Médical, Saint-Maur-des-Fossés, FranceSearch for more papers by this authorC. Garcia, C. Garcia Centre hospitalier Emile Roux, Le Puy-en-Velay, FranceSearch for more papers by this authorE. Estève, E. Estève Centre hospitalier d'Orléans, Orléans, FranceSearch for more papers by this authorR. Mohty, R. Mohty Cabinet Médical, Beauvais, Beauvais, FranceSearch for more papers by this authorL. Mery-Bossard, L. Mery-Bossard Saint-Germain-en-Laye, France, for the GEM ResoSearch for more papers by this authorF. Maccari, F. Maccari Hôpital d'Instruction des Armées Begin, Saint Mandé, France Cabinet Médical, Saint-Maur-des-Fossés, FranceSearch for more papers by this author Z. Reguiai, Corresponding Author Z. Reguiai [email protected] Department of Dermatology, Polyclinique Courlancy, Reims-Bezannes, France Correspondence Ziad REGUIAI, Postal address: Department of Dermatology, Polyclinique Courlancy-Bezannes, 89 rue Louis-Victor de Broglie, 51430 Bezannes. Email: [email protected], Tel: 0033352150808, Fax: 0033352150809Search for more papers by this authorP. A. Becherel, P. A. Becherel Dermatology and Clinical Immunology Unit, Antony Hospital, Antony, FranceSearch for more papers by this authorA. C. Fougerousse, A. C. Fougerousse orcid.org/0000-0002-2850-867X Hôpital d'Instruction des Armées Begin, Saint Mandé, FranceSearch for more papers by this authorG. Chaby, G. Chaby CHU Amiens- Picardie, Amiens, FranceSearch for more papers by this authorJ. L. Perrot, J. L. Perrot CHU Saint Etienne, Saint-Priest-en-Jarez, FranceSearch for more papers by this authorE. Begon, E. Begon Centre hospitalier René Dubos, Pontoise, FranceSearch for more papers by this authorC. Jacobzone-Lévêque, C. Jacobzone-Lévêque Centre hospitalier Bretagne Sud, Lorient, FranceSearch for more papers by this authorC. Boulard, C. Boulard GH, Le Havre, Montivilliers, FranceSearch for more papers by this authorA. Badaoui, A. Badaoui Cabinet Médical, Paris, FranceSearch for more papers by this authorC. Poreaux, C. Poreaux Centre de dermatologie Stanislas, , Nancy, Clinique Paster, Essey les Nancy, FranceSearch for more papers by this authorL. David, L. David Hopital Saint Joseph, Marseille, FranceSearch for more papers by this authorN. Quiles-Tsimaratos, N. Quiles-Tsimaratos Hopital Saint Joseph, Marseille, FranceSearch for more papers by this authorD. Lons-Danic, D. Lons-Danic Hôpital Paris Saint Joseph, Paris, FranceSearch for more papers by this authorC. Fite, C. Fite Hôpital Paris Saint Joseph, Paris, FranceSearch for more papers by this authorA.-L. Liegeon, A.-L. Liegeon Centre hospitalier régional Metz-Thionville, Thionville, FranceSearch for more papers by this authorA. Patchinsky, A. Patchinsky Centre hospitalier régional Metz-Thionville, Thionville, FranceSearch for more papers by this authorJ. Parier, J. Parier Centre de Santé Sabouraud, hôpital Saint-Louis, Paris, France Cabinet Médical, Saint-Maur-des-Fossés, FranceSearch for more papers by this authorC. Garcia, C. Garcia Centre hospitalier Emile Roux, Le Puy-en-Velay, FranceSearch for more papers by this authorE. Estève, E. Estève Centre hospitalier d'Orléans, Orléans, FranceSearch for more papers by this authorR. Mohty, R. Mohty Cabinet Médical, Beauvais, Beauvais, FranceSearch for more papers by this authorL. Mery-Bossard, L. Mery-Bossard Saint-Germain-en-Laye, France, for the GEM ResoSearch for more papers by this authorF. Maccari, F. Maccari Hôpital d'Instruction des Armées Begin, Saint Mandé, France Cabinet Médical, Saint-Maur-des-Fossés, FranceSearch for more papers by this author First published: 06 July 2023 https://doi.org/10.1111/jdv.19302 This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi:10.1111/jdv.19302. AboutPDF ToolsExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Accepted ArticlesAccepted, unedited articles published online and citable. The final edited and typeset version of record will appear in the future. RelatedInformation

Many patients are treated for glaucoma. Like other drugs, anti‐glaucoma eye drops may induce dermatological adverse effects. We aim to review the dermatological adverse effects secondary to the active agents in anti‐glaucoma eye drops through a literature review. In January 2020, we queried PubMed using the following MeSH terms: glaucoma/drug therapy or glaucoma, open angle/drug therapy cross‐referenced with parasympathomimetics/adverse effects or adrenergic agonists/adverse effects or carbonic anhydrase inhibitors/adverse effects or prostaglandins F, synthetic/adverse effects or adrenergic beta antagonists/adverse effects or ophthalmic solutions/adverse effects. The initial search identified 1128 studies, of which 49 were excluded for being in a foreign language, 15 for not involving eye drops, 968 for not focusing on adverse dermatological effects, and 11 for insufficient documentation or redundancy. After adding 38 linked studies, we finally analyzed 123 studies. The ocular and periocular dermatological adverse effects of eye drops are contact dermatitis, hyperpigmentation, prostaglandin analog periorbitopathy, mucous membrane pemphigoid, eyelash depigmentation, skin hypertrichosis, and rare cases of melanoma and skin depigmentation. The reported distant dermatological adverse effects are psoriasis, excessive sweating, lichen planus, alopecia, toxic epidermal necrolysis, erythema multiforme, erythroderma, subacute cutaneous lupus erythematosus, nail pigmentation, and bullous pemphigoid. Most of the cutaneous adverse effects of anti‐glaucoma eye drops are ocular and periocular and induced by prostaglandin analogs. Distant adverse effects are rare and sometimes questionable but should be kept in mind, especially mucous membrane pemphigoid, which could lead to blindness. The role of preservatives, such as benzalkonium chloride, should also be considered.